In controlled clinical studies, use of Epoetin alfa and other erythropoiesis-stimulating agents (ESAs) have shown: • shortened time to tumour progression in patients with advanced head and neck cancer receiving radiation therapy when administered to target a haemoglobin of greater than 14 g/ dl (8.7 mmol/ l), • shortened overall survival and increased deaths attributed to disease progression at 4 months in patients with metastatic breast cancer receiving chemotherapy when administered to target a haemoglobin of 12-14 g/ dl (7.5 -8.7 mmol/ l), increased risk of death when administered to target a haemoglobin of 12 g/ dl (7.5 mmol/ l) in patients with active malignant disease receiving neither chemotherapy nor radiation therapy.
Lühenenud üldist elulemust ja sagenenud surmajuhte, mis on seotud haiguse progresseerumisega 4 kuu jooksul metastaatilise rinnavähiga patsientidel, kes saavad keemiaravi, kui saavutatud hemoglobiini tase on 12- 14 g/ dl (7, 5- 8, 7 mmol/ l).